BBS-Bioactive Bone Substitutes Plc: Trading on BBS’s warrants begins on First North Growth Market Finland
BBS-Bioactive Bone Substitutes Plc Company Announcement 28 June 2022 17.00 (CEST)
Trading on warrants 1-2022 (TO1) ja 2-2022 (TO2) issued by BBS-Bioactive Bone Substitutes Plc (“BBS” or the “Company”) begins on First North Growth Market Finland approximately on 1 July 2022.
Since only 8,084 warrants of series 1-2022 (TO1) and 2-2022 (TO2) each were subscribed in Sweden by a total of 199 subscribers, the warrants will not be subject to trading on First North Growth Market Sweden. BBS will provide the investors who have subscribed for warrants in Sweden and whose warrants have been delivered through the book-entry system maintained by Euroclear Sweden AB instructions on how to convert their warrants into warrants that are in the book-entry system maintained by Euroclear Finland Oy which can be traded on First North Growth Market Finland. The instructions will be delivered in September.
BBS-BIOACTIVE BONE SUBSTITUTES PLC
For more information:
Ilkka Kangasniemi, CEO,
tel. +35840 7080307, e-mail: [email protected]
Liisa Hukka, CFO,
tel. +35840 0611038, e-mail: [email protected]
Nordic Certified Adviser AB, tel. +46 70 551 67 29, [email protected]
BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.
BBS-Bioactive Bone Substitutes Oyj:n shares have been listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
More information: www.bbs-artebone.fi
Physitrack Plc announces Appointment of Head of People, C-suite changes
Physitrack Plc (“Physitrack Group”, “the Company”) today announces the appointment of Mr Jack Goodwin as Head of People for the Physitrack Group. Mr Goodwin joins the Company from the UK Government's Cabinet Office, where he last oversaw a transformation programme for 330,000 employees under the...
LÖSEN AV OPTIONSPROGRAM 2020/23
Surgical Sciences optionsprogram 2020/23 har lösts in av optionsinnehavarna medförande en ökning av antalet aktier i bolaget med 225 000, till 51 026 236 aktier. Aktiekapitalet ökar som en följd av detta med 11 250 SEK till 2 551 312 SEK. I samband med detta har VD Gisli Hennermark löst in 37 500 op...
EXERCISE OF OPTIONS PROGRAM 2020/23
Surgical Science's options program 2020/23 has been redeemed by the option holders resulting in an increase in the number of shares in the company by 225,000, to 51,026,236 shares. As a result, the share capital increases by SEK 11,250 to SEK 2,551,312. In connection with this, CEO Gisli Hennerm...
Doxa har preliminärt erhållit accepter från ägare till cirka 90,8 procent av de utestående B-aktierna i Serneke
Detta pressmeddelande utgör inte ett erbjudande om eller inbjudan att teckna, förvärva eller sälja aktier eller andra värdepapper, vare sig direkt eller indirekt, i Australien, Brasilien, Färöarna, Förenade Arabemiraten, Hongkong, Indien, Japan, Kanada, Nya Zeeland, Ryssland, Belarus, Schweiz, Saudi...